The results suggested that MET fusions, such as PTPRZ1–MET in glioma and glioblastoma cells or KIF5B-MET and EPHB4-MET in lung cancer cells, can upregulate the expression and enhance the phosphorylation of the MET protein, even without HGF stimulation. The gene discussed is MET; the disease is central nervous system cancer.